U.S. patent application number 12/253955 was filed with the patent office on 2009-03-19 for method of treating or retarding the development of blindness.
This patent application is currently assigned to The Trustees of the University of Pennsylvania. Invention is credited to Gregory M. Acland, Gustavo D. Aguirre, Jean Bennett, William W. Hauswirth, Samuel G. Jacobson, Albert M. Maguire.
Application Number | 20090074723 12/253955 |
Document ID | / |
Family ID | 23087460 |
Filed Date | 2009-03-19 |
United States Patent
Application |
20090074723 |
Kind Code |
A1 |
Acland; Gregory M. ; et
al. |
March 19, 2009 |
Method of Treating or Retarding the Development of Blindness
Abstract
A method for treating an ocular disorder characterized by the
defect or absence of a normal gene in the ocular cells of a human
or animal subject involves administering to the subject by
subretinal injection an effective amount of a recombinant
adeno-associated virus carrying a nucleic acid sequence encoding
the normal gene under the control of a promoter sequence which
expresses the product of the gene in the ocular cells. The ocular
cells are preferably retinal pigment epithelial (RPE) cells, and
the gene is preferably an RPE-specific gene, e.g., RPE65. The
promoter is one that can express the gene product in the RPE cells.
Compositions for subretinal administration are useful in this
method.
Inventors: |
Acland; Gregory M.; (Kennett
Square, PA) ; Aguirre; Gustavo D.; (Ithaca, NY)
; Bennett; Jean; (Bryn Mawr, PA) ; Hauswirth;
William W.; (Gainesville, FL) ; Jacobson; Samuel
G.; (Penn Valley, PA) ; Maguire; Albert M.;
(Bryn Mawr, PA) |
Correspondence
Address: |
HOWSON AND HOWSON
SUITE 210, 501 OFFICE CENTER DRIVE
FT WASHINGTON
PA
19034
US
|
Assignee: |
The Trustees of the University of
Pennsylvania
Philadelphia
PA
The University of Florida Research Foundation, Inc.
Gainesville
FL
Cornell Research Foundation, Inc.
Ithaca
NY
|
Family ID: |
23087460 |
Appl. No.: |
12/253955 |
Filed: |
October 18, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11511201 |
Aug 28, 2006 |
|
|
|
12253955 |
|
|
|
|
10300720 |
Nov 20, 2002 |
|
|
|
11511201 |
|
|
|
|
PCT/US02/11314 |
Apr 11, 2002 |
|
|
|
10300720 |
|
|
|
|
60283766 |
Apr 13, 2001 |
|
|
|
Current U.S.
Class: |
424/93.2 ;
514/44R |
Current CPC
Class: |
C12N 15/8645 20130101;
C07K 14/705 20130101; A61K 48/0058 20130101; C12N 2830/008
20130101; C12N 2840/203 20130101; A61K 9/0048 20130101; A61P 27/02
20180101; A61K 38/52 20130101; A61K 48/0075 20130101; A61K 48/00
20130101; A61K 38/465 20130101; C12N 2750/14171 20130101; C12N
2750/14132 20130101; A61K 48/005 20130101; C12Y 301/01064 20130101;
C12N 2750/14142 20130101; A61K 38/51 20130101; C12N 7/00 20130101;
C12N 2750/14143 20130101; A61K 38/00 20130101; C12N 15/86 20130101;
C12N 2830/85 20130101; A61K 31/70 20130101 |
Class at
Publication: |
424/93.2 ;
514/44 |
International
Class: |
A61K 48/00 20060101
A61K048/00; A61K 31/7088 20060101 A61K031/7088; A61K 35/12 20060101
A61K035/12; A61K 35/76 20060101 A61K035/76; A61P 27/02 20060101
A61P027/02 |
Claims
1. A method for treating an ocular disorder characterized by the
defect or absence of a normal retinal pigment specific epithelial
65 (RPE65) gene in ocular cells of a subject, said method
comprising: administering to said subject by subretinal injection
an effective amount of a recombinant adeno-associated virus
serotype 1 (rAAV1) or 2 (rAAV2) carrying a nucleic acid sequence
encoding said normal RPE65 gene under the control of a promoter
sequence which expresses the product of said RPE65 gene in said
ocular cells.
2. The method according to claim 1, wherein said normal RPE65 gene
is obtained from the same subject species as the subject being
treated.
3. The method according to claim 1, wherein said promoter is a
cell-specific promoter.
4. The method according to claim 1, wherein said promoter is the
chicken beta actin promoter/CMV enhancer.
5. The method according to claim 1, wherein said ocular cells are
retinal pigment epithelial cells.
6. A composition for treating an ocular disorder characterized by
the defect or absence of a normal retinal specific pigment
epithelial 65 (RPE65) gene in the retinal pigment epithelial (RPE)
cells of a subject, said composition comprising: (i) an effective
amount of a recombinant adeno-associated virus (rAAV) serotype 1
(rAAV1) or 2 (rAAV2) carrying a nucleic acid sequence encoding said
normal RPE65 gene under the control of a promoter sequence which
expresses the product of said RPE65 gene in said RPE cells; (ii) at
least one carrier; and (iii) additional components suitable for
subretinal injection.
7. The method according to claim 6, wherein said effective amount
is 1.times.10.sup.9 to 2.times.10.sup.12 rAAV infectious units in a
volume of about 150 to about 800 .mu.l.
8. The method according to claim 7, wherein said effective amount
is about 1.times.10.sup.10 to 2.times.10.sup.11 rAAV infectious
units in a volume of about 250 to about 500 .mu.l.
9. A method for treating Leber congenital amaurosis in a human,
said method comprising: administering to said human by subretinal
injection an effective amount of a recombinant adeno-associated
virus (rAAV) serotype 1 or 2 carrying a nucleic acid sequence
encoding a normal retinal specific pigment epithelial 65 (RPE65)
gene under the control of a promoter sequence which expresses the
product of said RPE65 gene in retinal pigment epithelial (RPE)
cells which contain a mutated version of said RPE65 gene, wherein
expression of said normal RPE65 gene provides to said RPE cells the
product necessary to restore or maintain vision in said human.
10. The method according to claim 9, wherein said promoter is
cell-specific.
11. The method according to claim 9, wherein said rAAV carries the
normal RPE65 gene.
12. The method according to claim 9, wherein said effective amount
is 1.times.10.sup.9 to 2.times.10.sup.12 rAAV infectious units in a
volume of about 150 to about 800 .mu.l.
13. The method according to claim 12, wherein said effective amount
is about 1.times.10.sup.10 to 2.times.10.sup.11 rAAV infectious
units in a volume of about 250 to about 500 .mu.l.
14. A method for treating an ocular disorder characterized by the
defect or absence of a normal retinal specific pigment epithelial
65 (RPE65) gene in the retinal pigment epithelial (RPE) cells of a
subject selected from the group consisting of a primate, canine,
and human, said method comprising: administering to said subject by
subretinal injection an effective amount of a recombinant
adeno-associated virus serotype 2 (rAAV2) carrying a nucleic acid
sequence encoding said normal RPE65 gene under the control of a
promoter sequence which expresses the product of said RPE65 gene in
said RPE cells.
15. The method according to claim 14, wherein said subject is a
canine or human.
16. The method according to claim 14, wherein said effective amount
is 1.times.10.sup.9 to 2.times.10.sup.12 rAAV2 infectious units in
a volume of about 150 to about 800 .mu.l.
17. The method according to claim 16, wherein said effective amount
is 1.times.10.sup.10 to 2.times.10.sup.11 rAAV2 infectious units in
a volume of about 250 to about 500 .mu.l.
18. A method for treating an ocular disorder characterized by the
defect or absence of a normal retinal specific pigment epithelial
65 (RPE65) gene in the retinal pigment epithelial cells (RPE) of a
subject, said method comprising: administering to said subject by
subretinal injection of a recombinant adeno-associated virus
serotype 1 (rAAV1) carrying a nucleic acid sequence encoding said
normal RPE65 gene under the control of a promoter sequence which
expresses the product of said RPE65 gene in said RPE cells, wherein
said rAAV1 is present in an amount of 1.times.10.sup.9 to
2.times.10.sup.12 rAAV1 infectious units in a volume of about 150
to about 800 .mu.l.
19. The method according to claim 18, wherein said rAAV1 amount is
about 1.times.10.sup.10 to 2.times.10.sup.11 rAAV1 infectious units
in a volume of about 250 to about 500 .mu.l.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. patent
application Ser. No. 11/511,201, filed Aug. 28, 2006, which is a
continuation of U.S. patent application Ser. No. 10/300,720, filed
Nov. 20, 2002, now abandoned, which is a continuation of
International Patent Application No. PCT/US02/11314, filed Apr. 11,
2002, which claims the benefit of the priority of U.S. Provisional
Patent Application No. 60/283,766, filed Apr. 13, 2001, now
abandoned.
BACKGROUND OF THE INVENTION
[0002] The invention relates generally to the use of recombinant
viruses to deliver a desired transgene to retinal pigment
epithelial cells of patients suffering from retinal degenerative
diseases.
[0003] The relationship between the neurosensory photoreceptors and
the adjacent retinal pigment epithelium (RPE) controls not only
normal retinal function, but also the pathogenesis of hereditary
retinal degenerations. Recent progress has identified the molecular
bases for primary photoreceptor diseases, such as retinitis
pigmentosa (Dna, T. P., et al. 1990 Nature 343, 364-366; Farrar, G.
J., et al. 1991 Nature 354, 478-480; and McLaughlin, M. E. et al,
1993 Nature Genetics 4, 130-134). Similarly the molecular bases for
RPE diseases that cause photoreceptor blindness, such as
child-onset severe retinal dystrophy, Leber's congenital amaurosis,
and Best macular dystrophy, have been identified (Gu, S.-M., et al.
1997 Nature Genetics 17, 194-197; Marlhens, F., et al. 1997 Nature
Genetics 17, 139-141; Petrukin, K., et al. 1998 Nature Genet 19,
241-247; and D'Cruz, P., et al. 2000 Hum. Mol Genet. 9, 645-651).
Despite these reported scientific advances, effective therapy for
human retinal degenerations is still lacking.
[0004] Retinal gene therapy has been considered a possible
therapeutic option for man. For example, U.S. Pat. No. 5,827,702
refers to methods for generating a genetically engineered ocular
cell by contacting the cell with an exogenous nucleic acid under
conditions in which the exogenous nucleic acid is taken up by the
cell for expression. The exogenous nucleic acid is described as a
retrovirus, an adenovirus, an adeno-associated virus or a plasmid.
See, also, International Patent Publication Nos. WO 00/15822,
published Mar. 23, 2000 and WO 98/48097, published Oct. 29,
1998.
[0005] A review of gene therapy efforts to date indicates that such
efforts have focused mainly on slowing down retinal degeneration in
rodent models of primary photoreceptor diseases. Normal genes and
mutation-specific ribozymes delivered to photoreceptors have
prolonged the lifetime of these cells otherwise doomed for
apoptotic cell death (Bennett, J., et al. 1996 Nat. Med. 2,
649-654; Bennett, J., et al. 1998 Gene Therapy 5, 1156-1164;
Kumar-Singh, R. & Farber, D., 1998 Hum. Mol. Genet. 7,
1893-900; Lewin, A. S., et al. 1998 Nat. Med. 4, 967-971; Ali, R.,
et al. 2000 Nat. Genet. 25, 306-310; Takahashi, M. et al, 1999 J.
Virol. 73, 7812-6; Lau, D., et al. 2000 Invest. Opthalmol. Vis.
Sci. 41, 3622-3633; and LaVail, M. M., et al. 2000 Proc Natl Acad
Sci USA 97, 11488-11493).
[0006] Retinal gene transfer of a reporter gene, green fluorescent
protein, using a recombinant adeno-associated virus was
demonstrated in normal primates (Bennett, J., et al. 1999 Proc.
Natl. Acad. Sci. USA 96, 9920-9925). However, an as-yet unmet goal
of research is the restoration of vision in a blinding disease of
animals, particularly humans and other mammals, caused by genetic
defects in RPE and/or photoreceptor cells.
[0007] There remains a need in the art for methods for effectively
treating humans and other mammals or other animals suffering from
blindness due to genetic defects or deficiencies, so as to restore
sufficient vision to enable the subject to function in response to
visual cues.
SUMMARY OF THE INVENTION
[0008] In one aspect, the invention provides a method for treating
an ocular disorder in a human or animal subject characterized by
the defect or absence of a normal gene in the ocular cells. The
method includes administering to the subject by subretinal
injection an effective amount of a recombinant adeno-associated
virus carrying a nucleic acid sequence encoding the normal gene
under the control of a promoter sequence which expresses the
product of the gene in the ocular cells.
[0009] In another aspect, the invention provides a method for
treating an ocular disorder in a human or animal subject
characterized by the defect or absence of a normal gene in the
retinal pigment epithelial (RPE) cells of the subject. The method
involves administering to the subject by subretinal injection an
effective amount of a recombinant virus carrying a nucleic acid
sequence encoding a normal retinal pigment epithelial (RPE)
cell-specific gene under the control of a promoter sequence which
expresses the product of the gene in RPE cells. In one embodiment,
the gene is the RPE65 gene.
[0010] In another aspect, the invention provides a method for
treating Leber congenital amaurosis in a subject by administering
to the subject by subretinal injection an effective amount of a
recombinant virus carrying a nucleic acid sequence encoding a
normal gene under the control of a promoter sequence which
expresses the product of the gene in ocular cells, wherein the
cells contain a mutated version of the gene. Expression of the
normal gene provides to the cells the product necessary to restore
or maintain vision in the subject. In one embodiment, the cells are
RPE or photoreceptor cells, and the promoters are cell-specific
promoters.
[0011] In still another embodiment, the invention provides a
composition for treatment of an ocular disorder characterized by
the defect or absence of a normal gene in the ocular cells of the
subject. Such compositions comprise effective amounts of a
recombinant adeno-associated virus carrying a nucleic acid sequence
encoding the normal gene under the control of a promoter sequence
which expresses the product of the gene in the ocular cells,
formulated with a carrier and additional components suitable for
subretinal injection. In one embodiment, the normal gene is
RPE65.
[0012] Other aspects and advantages of the present invention are
described further in the following detailed description of the
preferred embodiments thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0013] The invention provides a method for treating an ocular
disorder in a human, other mammalian or other animal subject. In
particular, the ocular disorder is one which involves a mutated or
absent gene in a retinal pigment epithelial cell or a photoreceptor
cell. The method of this invention comprises the step of
administering to the subject by subretinal injection an effective
amount of a recombinant virus carrying a nucleic acid sequence
encoding an ocular cell-specific normal gene operably linked to, or
under the control of, a promoter sequence which directs the
expression of the product of the gene in the ocular cells and
replaces the lack of expression or incorrect expression of the
mutated or absent gene.
A. THE OCULAR DISORDER
[0014] In particular, this method is useful for the treatment
and/or restoration of at least partial vision to subjects that have
lost vision due to ocular disorders, such as RPE-associated
retinopathies, which are characterized by a long-term preservation
of ocular tissue structure despite loss of function and by the
association between function loss and the defect or absence of a
normal gene in the ocular cells of the subject. A variety of such
ocular disorders are known, such as childhood onset blinding
diseases, retinitis pigmentosa, macular degeneration, and diabetic
retinopathy, as well as ocular blinding diseases known in the art.
It is anticipated that these other disorders, as well as blinding
disorders of presently unknown causation which later are
characterized by the same description as above, may also be
successfully treated by this method. Thus, the particular ocular
disorder treated by this method may include the above-mentioned
disorders and a number of diseases which have yet to be so
characterized. For purposes of illustration of this invention, the
particular ocular disorder being treated in the examples is Leber
congenital amaurosis, which affects humans. However, this invention
is not limited to the treatment of that disorder alone.
[0015] Leber congenital amaurosis (LCA) is a severe childhood-onset
blinding disease which can be caused by mutations in the retinal
pigment epithelium (RPE)-specific gene, RPE65. A
naturally-occurring large animal model of an analogous severe
disease of retinal degenerations is the RPE65 mutant dog. LCA
causes near total blindness from early in life. Among the molecular
causes of LCA are mutations in the gene encoding an RPE protein,
RPE65. RPE65 is an evolutionarily-conserved 65 kDa
membrane-associated protein (Redmond, T. & Hamel, C. 2000 Meth.
Enzymol. 317, 705-724 and Bavik, C. et al, 1992 J. Biol. Chem. 267,
23035-23042), which is important in retinoid metabolism (Saari, J.
2000 Invest Opthalmol Vis Sci 41, 337-348; Ma, J.-X. et al, 1998 J
Biol Chem 1443, 255-261; and Simon, A. et al, 1995 J Biol Chem 270,
1107-1112). Currently there is no treatment for LCA and related
early onset retinal degenerative diseases.
[0016] RPE65 deficiency in mice results in accumulation of
all-trans-retinyl esters, undetectable levels of rhodopsin, rod
photoreceptor dysfunction, inclusions in the RPE, and slow retinal
degeneration. The compound 9-cis-retinal can restore visual pigment
and function in RPE65-deficient mice (Redmond, T., et al. 1998 Nat.
Genet 20, 344-351 and Van Hooser, J. P., et al. 2000 Proc. Natl
Acad Sci USA 97, 8623-8628).
[0017] The RPE65 mutant dog shows early and severe visual
impairment caused by a homozygous 4 bp-deletion in the RPE65 gene.
The deletion results in a frame shift leading to a premature stop
codon, eliminating more than two-thirds of the wildtype
polypeptide. Histopathology in homozygotes shows prominent RPE
inclusions and slightly abnormal rod photoreceptor morphology
present within the first year of life, and slowly progressive
photoreceptor degeneration in older dogs. See, e.g., Wrigstad, A.
Hereditary Dystrophy of the Retina and the Retinal Pigment
Epithelium in a Strain of Briard Dogs: A Clinical, Morphological
and Electrophysiological Study. Linkoping University Medical
Dissertations (1994); Narfstrom, K. et al, 1989 Brit J. Opthalmol.
73, 750-756; and Aguirre, G., et al. 1998 Mol. Vis. 4, 23.
B. VECTORS FOR USE IN THE METHOD
[0018] According to the various embodiments of the present
invention, a variety of known nucleic acid vectors may be used in
these methods, e.g., recombinant viruses, such as recombinant
adeno-associated virus (AAV), recombinant adenoviruses, recombinant
retroviruses, recombinant poxviruses, and other known viruses in
the art, as well as plasmids, cosmids and phages, etc. A wealth of
publications known to those of skill in the art discusses the use
of a variety of such vectors for delivery of genes (see, e.g.,
Ausubel et al., Current Protocols in Molecular Biology, John Wiley
& Sons, New York, 1989; Kay, M. A. et al, 2001 Nat. Medic.,
7(1):33-40; and Walther W. and Stein U., 2000 Drugs, 60(2):249-71).
In one embodiment of this invention the vector is a recombinant AAV
carrying a wildtype (i.e., normal) version of a selected
transgene-encoding cDNA driven by a promoter that expresses the
product of the wildtype cDNA in selected ocular cells of the
affected subject. Methods for assembly of the recombinant vectors
are well-known (see, e.g., International Patent Publication No. WO
00/15822, published Mar. 23, 2000 and other references cited
herein). To exemplify the methods and compositions of this
invention, the presently preferred vector, a recombinant AAV is
described in detail.
[0019] 1. AAV Vectors
[0020] Adeno-associated viruses are small, single-stranded DNA
viruses which require helper virus to facilitate efficient
replication (K. I. Berns, Parvoviridae: the viruses and their
replication, p. 1007-1041, in F. N. Fields et al., Fundamental
Virology, 3rd ed., vol. 2, (Lippencott-Raven Publishers,
Philadelphia, Pa.) (1995)). The 4.7 kb genome of AAV is
characterized by two inverted terminal repeats (ITR) and two open
reading frames which encode the Rep proteins and Cap proteins,
respectively. The Rep reading frame encodes four proteins of
molecular weight 78 kD, 68 kD, 52 kD and 40 kD. These proteins
function mainly in regulating AAV replication and rescue and
integration of the AAV into a host cell's chromosomes. The Cap
reading frame encodes three structural proteins of molecular weight
85 kD (VP 1), 72 kD (VP2) and 61 kD (VP3) (Berns, cited above)
which form the virion capsid. More than 80% of total proteins in
AAV virion comprise VP3.
[0021] Flanking the rep and cap open reading frames at the 5' and
3' ends are 145 bp inverted terminal repeats (ITRs), the first 125
bp of which are capable of forming Y- or T-shaped duplex
structures. The two ITRs are the only cis elements essential for
AAV replication, rescue, packaging and integration of the AAV
genome. There are two conformations of AAV ITRs called "flip" and
"flop". These differences in conformation originated from the
replication model of adeno-associated virus which uses the ITR to
initiate and reinitiate the replication (R. O. Snyder et al, 1993,
J. Virol., 67: 6096-6104 (1993); K. I. Berns, 1990 Microbiological
Reviews, 54: 316-329). The entire rep and cap domains can be
excised and replaced with a therapeutic or reporter transgene (B.
J. Carter, in "Handbook of Parvoviruses", ed., P. Tijsser, CRC
Press, pp. 155-168 (1990)).
[0022] AAVs have been found in many animal species, including
primates, canine, fowl and human (F. A. Murphy et al, "The
Classification and Nomenclature of Viruses: Sixth Report of the
International Committee on Taxonomy of Viruses", Archives of
Virology, (Springer-Verlag, Vienna) (1995)). Six primate serotypes
have been reported (AAV1, AAV2, AAV3, AAV4, AAV5 and AAV6). The AAV
ITR sequences and other AAV sequences employed in generating the
minigenes, vectors, and capsids, and other constructs used in the
present invention may be obtained from a variety of sources. For
example, the sequences may be provided by AAV type 5, AAV type 2,
AAV type 1, AAV type 3, AAV type 4, AAV type 6, or other AAV
serotypes or other adenoviruses, including presently identified
human AAV types and AAV serotypes yet to be identified. Similarly,
AAVs known to infect other animals may also provide these ITRs
employed in the molecules or constructs of this invention.
Similarly, the capsids from a variety of serotypes of AAV may be
"mixed and matched" with the other vector components. See, e.g.,
International Patent Publication No. WO 01/83692, published Nov. 8,
2001, and incorporated herein by reference. A variety of these
viral serotypes and strains are available from the American Type
Culture Collection, Manassas, Va., or are available from a variety
of academic or commercial sources. Alternatively, it may be
desirable to synthesize sequences used in preparing the vectors and
viruses of the invention using known techniques, which may utilize
AAV sequences which are published and/or available from a variety
of databases. The source of the sequences utilized in preparation
of the constructs of the invention, is not a limitation of the
present invention. Similarly, the selection of the species and
serotype of AAV that provides these sequences is within the skill
of the artisan and does not limit the following invention.
[0023] 2. The Minigene
[0024] For use in the present invention, the AAV sequences are
typically in the form of a rAAV construct (e.g., a minigene or
cassette) which is packaged into a rAAV virion. At a minimum, the
rAAV minigene useful in this invention is formed by AAV inverted
terminal repeat sequences (ITRs) and a heterologous molecule for
delivery to a host cell. Most suitably, the minigene contains AAV
5' ITRs and 3' ITRs located 5' and 3' to the heterologous molecule,
respectively. However, in certain embodiments, it may be desirable
for the minigene to contain the 5' ITR and 3' ITR sequences
arranged in tandem, e.g., 5' to 3' or a head-to-tail, or in another
alternative configuration. In still other embodiments, it may be
desirable for the minigene to contain multiple copies of the ITRs
or to have 5' ITRs (or conversely, 3' ITRs) located both 5' and 3'
to the heterologous molecule. The ITRs sequences may be located
immediately upstream and/or downstream of the heterologous
molecule, or there may be intervening sequences. The ITRs may be
selected from AAV5, or from among the other AAV serotypes, as
described herein. Optionally, a minigene may contain 5' ITRs from
one serotype and 3' ITRs from a second serotype. The AAV sequences
employed are preferably the 145 bp cis-acting 5' and 3' inverted
terminal repeat sequences (See, e.g., B. J. Carter, cited above).
Preferably, the entire sequences encoding the ITRs are used in the
molecule, although some degree of minor modification of these
sequences is permissible. The ability to modify these ITR sequences
is within the skill of the art. (See, e.g., texts such as Sambrook
et al, "Molecular Cloning. A Laboratory Manual", 2d ed., Cold
Spring Harbor Laboratory, New York (1989); Carter et al, cited
above; and K. Fisher et al., 1996 J. Virol., 70:520-532). One of
skill in the art can readily engineer the rAAV virus by methods
known to the art (e.g., Bennett, J., et al. 1999 Proc. Natl. Acad.
Sci. USA 96, 9920-9925). An example of such a molecule employed in
the present invention is a "cis-acting" plasmid containing the
heterologous molecule flanked by the 5' and 3' AAV ITR
sequences.
[0025] The heterologous molecule may be any substance which is
desired to be delivered to a cell, including, without limitation, a
polypeptide, protein, enzyme, carbohydrate, chemical moiety, or
nucleic acid sequences which may include oligonucleotides, RNA,
and/or DNA. Preferably, for use in this invention, the heterologous
molecule is a selected transgene under the control of a selected
promoter and other conventional vector regulatory components. See,
e.g., U.S. Pat. Nos. 5,856,152 and 5,871,982. In one embodiment,
the heterologous molecule may be a nucleic acid molecule which
introduces specific genetic modifications into human chromosomes,
e.g., for correction of mutated genes. See, e.g., D. W. Russell
& R. K. Hirata, 1998 Nat. Genet., 18:325-330.
[0026] a. The Transgene
[0027] In another desirable embodiment, the heterologous molecule
is a nucleic acid molecule is a transgene. As used herein,
"transgene" refers to a nucleic acid sequence heterologous to the
AAV sequence, encoding a desired product, e.g., a polypeptide or
protein of interest, and the regulatory sequences which direct
transcription and/or translation thereof in a host cell, and permit
expression of the encoded product in a host cell. Suitable encoded
products and regulatory sequences are discussed in more detail
below. However, the selection of the heterologous molecule
delivered by the AAV minigene is not a limitation of the present
invention.
[0028] In one embodiment of the method, where the ocular disorder
is caused by a mutation in a normal retinal pigment epithelium
(RPE)-specific gene, the ocular cells which are the target of the
treatment method are the retinal pigment epithelial (RPE) cells.
The specific gene which is mutated or absent in the disorder may be
the RPE65 gene. Another gene which is mutated or absent in the
disorder in humans may be the arylhydrocarbon-interacting receptor
protein like 1 (AIPL1). Thus, the normal gene, i.e., the transgene,
present in the recombinant virus is the normal, species-matched
version of the mutated gene, e.g., wildtype canine RPE65 for the
treatment of canine LCA or wildtype human RPE65 for the treatment
of human LCA, wildtype human AIPL1 for the treatment of a certain
type of human blinding diseases, etc. In still another embodiment,
the gene can be the CRB1 (RP12) gene. In another embodiment, the
transgene can be the lecithin retinal acetyltransferase (LRAT)
gene. These transgenes, as well as other transgenes useful for
delivery to the eye may be obtained from conventional sources,
e.g., from university laboratories or depositories, or synthesized
from information obtained from Genbank by known techniques.
[0029] In another embodiment of the method, where the ocular
disorder is caused by a mutation in a normal photoreceptor-specific
gene, the ocular cells which are the target of the treatment method
are the photoreceptor cells. The specific gene which is mutated or
absent in the disorder may be the photoreceptor-specific homeo box
gene (CRX). Alternatively, the specific gene which is mutated or
absent in the disorder may be the retinal guanylate cyclase gene
(GUCY2D). In still another embodiment, the transgene is a
nucleotide sequence encoding RPGR Interacting Protein 1 (RPGRIP1).
Thus, the normal gene, i.e., the transgene, present in the
recombinant adeno-associated virus is the normal, species-matched
version of the mutated gene, e.g., wildtype murine CRX for the
treatment of the correlative murine blinding disorder or wildtype
human CRX for the treatment of the correlative human blinding
disorder, wildtype chicken GUCY2D for the treatment of the
correlative chicken blinding disorder or wildtype human GUCY2D for
the treatment of the correlative human blinding disorder, etc.
These transgenes may be obtained from conventional sources, e.g.,
from university laboratories or depositories, or synthesized from
information obtained from Genbank by known techniques.
[0030] As discussed above, still other genes may be added to this
list, including the LCA genes referred to as LCA3, located at
chromosome 14q24 and LCA5, located at chromosome 6q11-q16, among
others.
[0031] Genes responsible for disorders other than LCA may also be
employed as the transgene, as suitable ocular diseases are
identified. Thus, different transgene may be used in the design of
similar vectors of this invention for the treatment of disorders
other than LCA. Among the known genes which may be absent or
mutated in the blinding disorders identified above include
dystrophin, ABCR, EMP1, TIMP3, MERTCK and ELOVL4. One or more of
the wildtypes of these genes may be administered to ocular cells,
particularly the RPE, in the same manner as is the exemplified
RPE65 for the treatment of LCA. One of skill in the art may obtain
the appropriate gene sequences and design the appropriate vectors
for such use in view of this disclosure and in view of other
information known to the art.
[0032] In certain situations, a different transgene may be used to
encode each subunit of a protein, or to encode different peptides
or proteins. This is desirable when the size of the DNA encoding
the protein subunit is large, e.g., for an immunoglobulin, the
platelet-derived growth factor, or a dystrophin protein. In order
for the cell to produce the multi-subunit protein, a cell is
infected with the recombinant virus containing each of the
different subunits. In another embodiment, different subunits of a
protein may be encoded by the same transgene. In this case, a
single transgene includes the DNA encoding each of the subunits,
with the DNA for each subunit separated by an internal ribozyme
entry site (IRES). This is desirable when the size of the DNA
encoding each of the subunits is small, e.g., total of the DNA
encoding the subunits and the IRES is less than five kilobases.
Alternatively, other methods which do not require the use of an
IRES may be used for co-expression of proteins. Such other methods
may involve the use of a second internal promoter, an alternative
splice signal, a co- or post-translational proteolytic cleavage
strategy, among others which are known to those of skill in the
art.
[0033] b. Regulatory Sequences
[0034] The minigene or transgene includes appropriate sequences
that are operably linked to the nucleic acid sequences encoding the
product of interest to promote its expression in a host cell.
"Operably linked" sequences present in the minigene include both
expression control sequences (e.g. promoters) that are contiguous
with the coding sequences for the product of interest and
expression control sequences that act in trans or at a distance to
control the expression of the product of interest. In addition to
being useful in the transgene, the regulatory elements described
herein may also be used in other heterologous molecules and the
other constructs described in this application.
[0035] Expression control sequences include appropriate
transcription initiation, termination, promoter and enhancer
sequences; efficient RNA processing signals such as splicing and
polyadenylation signals; sequences that stabilize cytoplasmic mRNA;
sequences that enhance translation efficiency (i.e., Kozak
consensus sequence); sequences that enhance protein stability; and
when desired, sequences that enhance protein processing and/or
secretion. A great number of expression control sequences, e.g.,
native, constitutive, inducible and/or tissue-specific, are known
in the art and may be utilized to drive expression of the gene,
depending upon the type of expression desired.
[0036] For eukaryotic cells, expression control sequences typically
include a promoter, an enhancer, such as one derived from an
immunoglobulin gene, SV40, cytomegalovirus, etc., and a
polyadenylation sequence which may include splice donor and
acceptor sites. The polyadenylation sequence generally is inserted
following the transgene sequences and before the 3' ITR sequence.
In one embodiment, the bovine growth hormone polyA is used.
[0037] The regulatory sequences useful in the constructs of the
present invention may also contain an intron, desirably located
between the promoter/enhancer sequence and the gene. One possible
intron sequence is also derived from SV-40, and is referred to as
the SV-40 T intron sequence. Another suitable sequence includes the
woodchuck hepatitis virus post-transcriptional element. (See, e.g.,
L. Wang and I. Verma, 1999 Proc. Natl. Acad. Sci., USA,
96:3906-3910).
[0038] Another regulatory component of the rAAV useful in the
method of the invention is an internal ribosome entry site (IRES).
An IRES sequence, or other suitable systems as are discussed above,
may be used to produce more than one polypeptide from a single gene
transcript. An IRES (or other suitable sequence) is used to produce
a protein that contains more than one polypeptide chain or to
express two different proteins from or within the same cell. An
exemplary IRES is the poliovirus internal ribosome entry sequence,
which supports transgene expression in photoreceptors, RPE and
ganglion cells. Preferably, the IRES is located 3' to the transgene
in the rAAV vector.
[0039] The selection of the promoter to be employed in the rAAV may
be made from among a wide number of constitutive or inducible
promoters that can express the selected transgene in an ocular. In
a preferred embodiment, the promoter is cell-specific. The term
"cell-specific" means that the particular promoter selected for the
recombinant vector can direct expression of the selected transgene
is a particular ocular cell type. As one example, the promoter is
specific for expression of the transgene in RPE cells. As another
example, the promoter is specific for expression of the transgene
in photoreceptor cells.
[0040] Examples of constitutive promoters which may be included in
the rAAV of this invention include, without limitation, the
exemplified CMV immediate early enhancer/chicken .beta.-actin
(C.beta.A) promoter-exon 1-intron 1 element of Example 1, the RSV
LTR promoter/enhancer, the SV40 promoter, the CMV promoter, the
dihydrofolate reductase promoter, and the phosphoglycerol kinase
(PGK) promoter.
[0041] RPE-specific promoters include, for example, the RPE-65
promoter, the tissue inhibitor of metalloproteinase 3 (Timp3)
promoter, and the tyrosinase promoter. Still other RPE-specific
promoters are known to those of skill in the art. See, e.g., the
promoters described in International Patent Publication No. WO
00/15822.
[0042] Examples of photoreceptor specific promoters include,
without limitation, the rod opsin promoter, the red-green opsin
promoter, the blue opsin promoter, the inter photoreceptor binding
protein (IRBP) promoter and the cGMP-.beta.-phosphodiesterase
promoter. See, e.g., the promoters described in International
Patent Publication No. WO 98/48097.
[0043] Alternatively, an inducible promoter is employed to express
the transgene product, so as to control the amount and timing of
the ocular cell's production thereof. Such promoters can be useful
if the gene product proves to be toxic to the cell upon excessive
accumulation. Inducible promoters include those known in the art
and those discussed above including, without limitation, the
zinc-inducible sheep metallothionine (MT) promoter; the
dexamethasone (Dex)-inducible mouse mammary tumor virus (MMTV)
promoter; the T7 promoter; the ecdysone insect promoter; the
tetracycline-repressible system; the tetracycline-inducible system;
the RU486-inducible system; and the rapamycin-inducible system. Any
type of inducible promoter which is tightly regulated and is
specific for the particular target ocular cell type may be used.
Other types of inducible promoters which may be useful in this
context are those which are regulated by a specific physiological
state, e.g., temperature, acute phase, a particularly
differentiation state of the cell, or in replicating cells
only.
[0044] Selection of these and other common vector and regulatory
elements are conventional and many such sequences are available.
See, e.g., Sambrook et al, and references cited therein at, for
example, pages 3.18-3.26 and 16.17-16.27 and Ausubel et al.,
Current Protocols in Molecular Biology, John Wiley & Sons, New
York, 1989). Of course, not all vectors and expression control
sequences will function equally well to express all of the
transgenes of this invention. However, one of skill in the art may
make a selection among these expression control sequences without
departing from the scope of this invention. Suitable
promoter/enhancer sequences may be selected by one of skill in the
art using the guidance provided by this application. Such selection
is a routine matter and is not a limitation of the molecule or
construct. For instance, one may select one or more expression
control sequences, operably link the sequence to a transgene of
interest, and insert the "minigene" comprising the expression
control sequence and the transgene into an AAV vector. The vector
may be packaged into an infectious particle or virion following one
of the methods for packaging the rAAV taught in the art.
C. PRODUCTION OF THE rAAV
[0045] The rAAV virus of the invention may be constructed and
produced using the materials and methods described herein, as well
as those known to those of skill in the art. Such engineering
methods used to construct any embodiment of this invention are
known to those with skill in nucleic acid manipulation and include
genetic engineering, recombinant engineering, and synthetic
techniques. See, e.g., Sambrook et al, and Ausubel et al., cited
above; and International Patent Publication No. WO 95/13598.
Further, methods suitable for producing a rAAV cassette in an
adenoviral capsid have been described in U.S. Pat. Nos. 5,856,152
and 5,871,982.
[0046] Briefly, in order to package the rAAV construct into a rAAV
virion, a host cell must contain sequences necessary to express AAV
rep and AAV cap or functional fragments thereof as well as helper
genes essential for AAV production. For example, the rep78/52
proteins may be sufficient to provide the necessary rep functions.
The AAV rep and cap sequences are obtained from an AAV source as
identified above. The AAV rep and cap sequences may be introduced
into the host cell in any manner known to one in the art as
described above, including, without limitation, transfection,
electroporation, liposome delivery, membrane fusion techniques,
high velocity DNA-coated pellets, viral infection and protoplast
fusion. In one embodiment, the rep and cap sequences may be
transfected into the host cell by one or more nucleic acid
molecules and exist stably in the cell as an episome. In another
embodiment, the rep and cap sequences are stably integrated into
the genome of the cell. Another embodiment has the rep and cap
sequences transiently expressed in the host cell. For example, a
useful nucleic acid molecule for such transfection comprises, from
5' to 3', a promoter, an optional spacer interposed between the
promoter and the start site of the rep gene sequence, an AAV rep
gene sequence, and an AAV cap gene sequence.
[0047] The rep and cap sequences, along with their expression
control sequences, may be supplied on a single vector, or each
sequence may be supplied on its own vector. Preferably, the rep and
cap sequences are supplied on the same vector. Alternatively, the
rep and cap sequences may be supplied on a vector that contains
other DNA sequences that are to be introduced into the host cells.
Preferably, the promoter used in this construct may be any suitable
constitutive, inducible or native promoters known to one of skill
in the art. The molecule providing the rep and cap proteins may be
in any form which transfers these components to the host cell.
Desirably, this molecule is in the form of a plasmid, which may
contain other non-viral sequences, such as those for marker genes.
This molecule does not contain the AAV ITRs and generally does not
contain the AAV packaging sequences. To avoid the occurrence of
homologous recombination, other virus sequences, particularly those
of adenovirus, are avoided in this plasmid. This plasmid is
desirably constructed so that it may be stably transfected into a
cell.
[0048] Although the molecule providing rep and cap may be
transiently transfected into the host cell, it is preferred that
the host cell be stably transformed with sequences necessary to
express functional rep/cap proteins in the host cell, e.g., as an
episome or by integration into the chromosome of the host cell.
Depending upon the promoter controlling expression of such stably
transfected host cell, the rep/cap proteins may be transiently
expressed (e.g., through use of an inducible promoter).
[0049] The methods employed for constructing embodiments of this
invention are conventional genetic engineering or recombinant
engineering techniques such as those described in the references
above. For example, the rAAV may be produced utilizing a triple
transfection method using either the calcium phosphate method
(Clontech) or Effectene reagent (Qiagen, Valencia, Calif.),
according to manufacturer's instructions. See, also, Herzog et al,
1999, Nature Medic., 5(1):56-63, for the method used in the
following examples, employing the plasmid with the transgene,
CPA-RPE65, a helper plasmid containing AAV rep and cap, and a
plasmid supplying adenovirus helper functions of E2A, E4Orf6 and
VA. While this specification provides illustrative examples of
specific constructs, using the information provided herein, one of
skill in the art may select and design other suitable constructs,
using a choice of spacers, promoters, and other elements, including
at least one translational start and stop signal, and the optional
addition of polyadenylation sites.
[0050] The rAAV virions are then produced by culturing a host cell
containing a rAAV virus as described herein which contains a rAAV
construct to be packaged into a rAAV virion, an AAV rep sequence
and an AAV cap sequence under the control of regulatory sequences
directing expression thereof. Suitable viral helper genes, e.g.,
adenovirus E2A, E4Orf6 and VA, among other possible helper genes,
may be provided to the culture in a variety of ways known to the
art, preferably on a separate plasmid. Thereafter, the recombinant
AAV virion which directs expression of the transgene is isolated
from the cell or cell culture in the absence of contaminating
helper virus or wildtype AAV.
[0051] One may easily assay whether a particular expression control
sequence is suitable for a specific transgene, and choose the
expression control sequence most appropriate for expression of the
desired transgene. For example, a target cell may be infected in
vitro, and the number of copies of the transgene in the cell
monitored by Southern blotting or quantitative polymerase chain
reaction (PCR). The level of RNA expression may be monitored by
Northern blotting or quantitative reverse transcriptase (RT)-PCR;
and the level of protein expression may be monitored by Western
blotting, immunohistochemistry, enzyme-linked immunosorbent assay
(ELISA), radioimmunoassay (RIA) or by the specific methods detailed
below in the examples.
[0052] In one embodiment exemplified below, a suitable recombinant
vector for use in this invention is AAV-RPE65, which utilizes AAV
serotype 2 ITR and capsid sequences and is described in detail in
Example 1 below. This recombinant AAV contains a CMV immediate
early enhancer/chicken .beta.-actin (CPA) promoter-exon 1-intron 1
element followed by a poliovirus internal ribosome entry sequence
(IRES), followed by the cDNA encoding the wildtype protein RPE65.
However, the present invention is not limited to this exemplary
embodiment. Similar rAAV with different transgenes, promoters,
IRES, and virus capsids may be useful in this invention, as
described in detail above.
D. PHARMACEUTICAL COMPOSITIONS AND METHODS OF THE INVENTION
[0053] The recombinant AAV containing the desired transgene and
cell-specific promoter for use in the target ocular cell as
detailed above is preferably assessed for contamination by
conventional methods and then formulated into a pharmaceutical
composition intended for subretinal injection. Such formulation
involves the use of a pharmaceutically and/or physiologically
acceptable vehicle or carrier, particularly one suitable for
subretinal injection, such as buffered saline or other buffers,
e.g., HEPES, to maintain pH at appropriate physiological levels. A
variety of such known carriers are provided in International Patent
Publication No. WO 00/15822, incorporated herein by reference. If
the virus is to be stored long-term, it may be frozen in the
presence of glycerol.
[0054] According to the method of this invention for treating an
ocular disorder characterized by the defect or absence of a normal
gene in the ocular cells of a human or animal subject, the
pharmaceutical composition described above is administered to the
subject having such a blinding disease by subretinal injection. The
use of subretinal injection as the route of delivery is a critical
component of this method, as intravitreal administration does not
enable the same therapeutic effects. The vector and carrier cannot
diffuse across the multiple cell layers in the retina to reach the
RPE, when intravitreal injection is used. Similarly, intravenous
delivery is unacceptable because the material does not penetrate
the blood-brain (blood-retinal) barrier. Because the virus does not
diffuse well, topical administration is similarly not preferred for
this method. See the examples below.
[0055] An effective amount of a recombinant adeno-associated virus
carrying a nucleic acid sequence encoding the desired transgene
under the control of the cell-specific promoter sequence desirably
ranges between about 1.times.10.sup.9 to 2.times.10.sup.12 rAAV
infectious units in a volume of between about 150 to about 800
.mu.l. The rAAV infectious units are measured as described in S. K.
McLaughlin et al, 1988 J. Virol., 62: 1963. More desirably, an
effective amount is between about 1.times.10.sup.10 to
2.times.10.sup.11 rAAV infectious units in a volume of between
about 250 to about 500 .mu.l. Still other dosages in these ranges
may be selected by the attending physician, taking into account the
physical state of the subject, preferably human, being treated, the
age of the subject, the particular ocular disorder and the degree
to which the disorder, if progressive, has developed.
[0056] It may also be desirable to administer multiple "booster"
dosages of the pharmaceutical compositions of this invention. For
example, depending upon the duration of the transgene within the
ocular target cell, one may deliver booster dosages at 6 month
intervals, or yearly following the first administration. The fact
that AAV-neutralizing antibodies were not generated by
administration of the rAAV vector, as discussed in the examples
below, should allow additional booster administrations.
[0057] Such booster dosages and the need therefor can be monitored
by the attending physicians, using, for example, the retinal and
visual function tests and the visual behavior tests described in
the examples below. Other similar tests may be used to determine
the status of the treated subject over time. Selection of the
appropriate tests may be made by the attending physician. Still
alternatively, the method of this invention may also involve
injection of a larger volume of virus-containing solution in a
single or multiple infection to allow levels of visual function
close to those found in wildtype retinas.
[0058] As is demonstrated in the examples below, an exemplary
rAAVRPE65 was employed in in vitro and in vivo experiments to
provide evidence of the utility and efficacy of the methods and
compositions of this invention. The in vitro examples demonstrated
proper expression of the transgene in an animal model of a human
ocular disorder resulting in blindness. The in vivo examples
demonstrated restoration of visual function and visual behavior by
the method of this invention in a large animal model of a human
retinopathy. The use of the exemplary vector demonstrated in both
in vitro and in vivo experiments that the defect in the RPE65
mutant dog could be corrected by gene delivery. Vision was restored
in this large animal model of childhood blindness. This is the
first successful reversal of vision loss in a large animal model of
retinal degeneration. This data allow one of skill in the art to
readily anticipate that this method may be similarly used in
treatment of LCA or other types of retinal disease in other
subjects, including humans.
[0059] While previous studies have demonstrated that retinal
degeneration can be retarded with gene therapy techniques, the
present invention demonstrates a definite recovery of function. In
addition, while small animal studies have demonstrated histologic
and electrophysiologic correlates of visual function to be
partially preserved, this large animal study has shown the presence
of vision with regard to both physiological and behavioral
measures.
E. EXAMPLES
[0060] As summarized, the following examples demonstrate that in
three of three eyes, in vivo transfer of wildtype RPE65 to cells of
the outer retina was sufficient to restore photoreceptor function
in the RPE65 mutant dog. Function was not restored after
intravitreal injection of vector, a route which normally results
only in transduction of ganglion cells (Dudus, L., et al. Vision
Res. 39, 2545-2554 (1999)). The virus transduced RPE cells in the
immediately injected quadrant, and transduced RPE produced both
wildtype RPE65 message and protein. Without being bound by theory,
the inventors believe that although the rAAV virus targets
photoreceptors and other retinal neurons as well as RPE cells, and
the CPA promoter is active in all these cell types, it is likely
that it is the expression of the wildtype transgene in RPE cells
(and not photoreceptors) that rescues the mutant phenotype. The RPE
alone is responsible for, and possesses the components necessary to
supply chromophore for, rod photoreceptors, although the existence
of a retinal retinoid metabolism for cones (not involving RPE65
gene product) remains plausible.
[0061] The following examples illustrate several embodiments of
this invention. These examples are illustrative only, and do not
limit the scope of the present invention.
Example 1
Virus Preparation
[0062] Recombinant AAV vector was based on pTR-UF2, a vector using
the 472 bp mouse rod opsin promoter to drive expression of green
fluorescent protein (GFP) (Flannery, J., et al. 1997 Proc Natl Acad
Sci USA 94, 6916-6921). To generate the recombinant vector,
AAV-PPE65, the opsin promoter in pTR-UF2 was replaced with a CMV
immediate early enhancer (381 bp)/chicken .beta.-actin (CPA)
promoter-exon 1-intron 1 (1352 bp) element followed by a poliovirus
internal ribosome entry sequence (637 bp). The latter supports
expression in photoreceptors, RPE and ganglion cells (Li and
Hauswirth, unpublished data, 2000). The reporter/transgene GFP was
replaced with the canine RPE65 cDNA (Aguirre, G. et al, 1998 Mol.
Vis. 4: 23) via flanking Not I sites and the orientation and
reading frame confirmed by DNA sequence analysis. Plasmid DNA
containing this construct was packaged into AAV particles employing
iodixanol gradient purification followed by heparin-sepharose
agarose column chromatography as described in Hauswirth, W. W. et
al, 2000 Meth. Enzymol. 316, 743-761. Vector titers were determined
using an infectious center assay.
[0063] Four AAV-RPE65 virus preparations were made and combined to
a total volume of 1.05 ml at 2.3.times.10.sup.11 infectious
particles/ml. Contaminating helper adenoviras and wild-type AAV,
assayed by serial dilution cytopathic effect or infectious center
assay, respectively were less than six orders of magnitude lower
than vector AAV.
Example 2
In Vitro Testing of an AAV Carrying the Wildtype Canine RPE65
cDNA
[0064] A. RPE Cell Cultures
[0065] RPE cells from eyes of both a wildtype dog and a homozygous
affected (RPE65 mutant) dog were dissociated with 0.25% trypsin
(Ray, J. et al, 1997 Curr. Eye Res. 16: 131-143) and plated at
1-2.times.10.sup.5/9 mm plastic dish. The cells were then cultured.
After 48 days, confluent RPE cultures were trypsinized, subcultured
and infected at 80% confluency with 2.3.times.10.sup.7 AAV-RPE65
viral particles for 4 hours. Expression of the RPE65 transgene was
assessed by immunohistochemistry 10 days post-infection.
[0066] B. RPE65 Immunocytochemistry and Western Analysis in Canine
RPE Cells and Retina.
[0067] In order to evaluate the presence of the RPE65 protein, the
cultured canine RPE cells were evaluated by immunocytochemistry by
immunolabelling with a rabbit anti-RPE65 peptide polyclonal
antibody (generously provided by T. M. Redmond) and the nuclei were
stained with propidium iodide. For Western analysis, proteins from
cultured RPE were electrophoresed on 12.5% SDS-polyacrylamide gel
and then electrotransferred on nitrocellulose membrane.
Immunodetection was performed using the anti-RPE65 antibody
followed by goat anti-rabbit secondary antibody and
.sup.125I-protein A (Verdugo, M., et al. 1998 Invest Opthalmol Vis
Sci 39, S719).
[0068] In the resulting immunohistochemical sections (not shown)
wildtype retinal cells labeled uniformly and intensely with the
anti-RPE65 antibody, i.e., they possessed high levels of RPE65. In
contrast, RPE65 labeling (i.e., RPE protein) was absent in
untreated RPE65 mutant cells, 60 days in culture, prior to
infection with AAV-RPE65, showing only background autofluorescence.
Further, lipid inclusions were apparent in the diseased RPE cells.
However, within 10 days of infection of the RPE65 mutant cells (60
days in culture) with AAV-RPE65, the majority of cells labeled
positively with the anti-RPE65 antibody, indicating presence of
wildtype RPE65 protein. One cell did not appear to have been
transduced. Complementary results were observed following
immunohistochemistry of sections from untreated wildtype versus
mutant RPE65+ canine retinas.
[0069] Infection of the defective RPE cells by AAV-RPE65 and
subsequent expression of the wildtype RPE65 transgene were further
confirmed in vitro using PCR amplification and Western analysis,
respectively.
[0070] PCR studies took advantage of the difference in size of the
wildtype versus mutant canine RPE65 transcripts due to the 4 bp
deletion in the latter. PCR amplification utilized RPE65-1
(forward) and RPE65-3 (reverse) primers flanking the RPE65 mutant
deletion site (Aguirre, G. et al, 1998 Mol. Vis. 4:23). PCR
conditions were 94.degree. C. (30 seconds), 60.degree. C. (30
seconds), and 72.degree. C. (1 minute) for 34 cycles. PCR products
were separated on a 6% polyacrylamide gel. AAV-RPE65 was used as
positive control. This protocol was also used for PCR screening for
shedding virus.
[0071] The PCR primers flanking this region amplified the wildtype
109 bp RPE65 DNA fragment in transduced RPE cells from an affected
dog. Non-transduced RPE from the same animal yielded only mutant
DNA (105 bp) and normal RPE yielded only the wildtype allele (109
bp). Expression of wildtype RPE65 in transduced RPE cells from an
affected animal was also apparent by Western blot analysis of cell
lysates. RPE65 expression was detected only in the transduced RPE
cells; not in uninfected cells.
Example 3
In Vivo Studies in the RPE65 Mutant Dog
[0072] A. Ocular Delivery
[0073] Effects of intraocular delivery of AAV-RPE65 were studied in
four RPE65 mutant dogs. For in vivo studies, virus was delivered
subretinally or intravitreally under direct surgical visualization
using methods described previously (Bennett, J., et al. 1999 Proc.
Natl. Acad. Sci. USA 96, 9920-9925 and Bennett, J. et al, 2000
Meth. Enzymol. 316, 777-789). Five eyes from three dogs (BR29, BR33
and BR47) were injected either subretinally or intravitreally with
AAV-RPE65; the sixth eye was untreated (Table 1). The fourth dog
(BR46) was maintained as an untreated control.
[0074] Each 150-200 .mu.l subretinal injection of vector (at a
concentration of 2.3.times.10.sup.11 infectious particles/ml)
created a retinal detachment elevating approximately 35% of the
total retinal area. In 2 eyes (BR33 and BR47) this detachment
primarily occupied the nasal-inferior quadrant; in the 3rd eye
(BR29) the site was temporal-superior. These detachments resolved
spontaneously within 24 hours. Animals were evaluated
post-operatively for evidence of ocular or systemic toxicity, virus
exposure to extralocular tissue, virus shedding, unfavorable immune
response or other untoward effects. As discussed in detail below,
none was found.
[0075] B. Detection of Inflammation
[0076] Eyes were evaluated clinically at regular intervals
following the surgery to identify inflammation. Humoral and
intraocular antibodies specific to AAV capsid proteins were
evaluated as described in Benneft, J., et al. 1999 Proc. Natl.
Acad. Sci. USA 96, 9920-9925, incorporated herein by reference.
Post-operatively, there was no evidence of ocular or systemic
toxicity, or other untoward effect. Hematology and blood
chemistries revealed no evidence of systemic toxicity. Evaluation
of humoral response prior to and post treatment revealed slightly
elevated anti-AAV capsid titers in pre-treatment serum samples,
suggesting previous exposure to AAV proteins. Antibody titers were
increased in two of the three dogs one month after exposure and in
all three dogs 4 months after exposure. Non-neutralizing serum
antibodies directed against RPE65 protein also increased after
intraocular exposure to AAV-RPE65.
[0077] C. Transgene Expression and Persistence
[0078] To correlate transgene expression with changed visual
function, one subretinally injected eye (BR29, right eye) was
surgically enucleated 99 days post injection. The eyecup was
divided into temporal-superior, temporal-inferior, nasal-superior,
and nasal-inferior quadrants. From each quadrant, the retina, and
the pooled RPE-plus-choroid tissues, were separately harvested and
dissected under RNase free conditions and rapidly frozen. Total RNA
was prepared from retina and RPE/choroid using the TRIzol Reagent
kit (Life Technologies, Gaithersburg, Md.). DNA was extracted from
the same tissues according to the vendor's protocol. cDNA was
amplified from total RNA using RNA PCR kit (Perkin Elmer, Foster
City, Calif.) and the conditions listed above.
[0079] RPE65 expression in neural retina, RPE/choroid, and cultured
RPE cells were detected. Genomic PCR demonstrates persistence of
transferred viral DNA in neural retina and RPE-choroid from the
injected temporal-superior quadrant. In other quadrants, the host
DNA amplified preferentially and the viral DNA amplification
product is below detectable levels. From noninfected RPE of the
affected dog, only mutant product amplifies, but 10 days
posttransfection in vitro the normal transgene yields the
overwhelming product.
[0080] RT-PCR (figures not shown) demonstrated expression of
wildtype message in neural retina from all 4 quadrants, but in
RPE-choroid from the injected quadrant only. Where both products
amplify, additional bands representing heteroduplexes are also
seen. The transfected RPE/choroid from the injected quadrant
expressed higher levels of the transferred cDNA than of the mutant
host gene. This was not so in other quadrants. Although
transfection of neural retina led to expression of the wildtype
allele in all quadrants, a gradient was present in the relative
intensities of the two alleles among quadrants. In the injected
quadrant, the wildtype allele yielded a much more intense band than
the host mutant allele. From the quadrant below this, the two bands
were approximately equal in intensity. In the nasal half of the
eye, the mutant band predominated.
[0081] Western analysis demonstrated absence of RPE65 protein in
mutant RPE cells prior to transfection, but presence of the protein
afterwards. Proteins were labeled with anti-RPE65 antibody.
[0082] By PCR analyses of serum and tear fluid, there was no sign
of virus shedding at 1 month after injection (data not shown).
Reverse transcriptase (RT)-PCR on sera, conjunctiva, eyelids, the
gland of the third eyelid, and the optic nerve from the enucleated
eye of BR29 were negative for the transgene at 103 days post
injection, indicating that virus escape to extraocular tissues was
below detectable levels.
D. RETINAL/VISUAL FUNCTION TESTING
1. Electroretinograms (ERGS)
[0083] The physiological consequences of the treatments were
assessed by electroretinography (ERG) (Banin, E., et al. 1999
Neuron 23, 549-57). Dogs were dark-adapted (overnight),
premedicated with acepromazine (0.55 mg/kg, IM) and atropine (0.03
mg/kg, IM) and anesthetized by intermittent ketamine (15 mg/kg, IV,
repeated every 15 minutes). Pulse rate, oxygen saturation and
temperature were monitored throughout. The cornea was anesthetized
with topical proparacaine HCl (1%) and pupils dilated with
cyclopentolate (1%) and phenylephrine (2.5%).
[0084] Full field ERGs were recorded using a computer-based system
(EPIC-XL, LKC Technologies, Inc., Gaithersburg, Md.) and
Burian-Allen contact lens electrodes (Hansen Ophthalmics, Iowa
city, Ia.) (Banin, E., et al. 1999 Neuron 23, 549-57). Dark-adapted
luminance-response functions were obtained with blue (Wratten 47A)
flash stimuli spanning .about.6 log units (-2.9 to +2.8 log
scot-cd.s.m.sup.-2).
[0085] ERG b-wave amplitudes were measured conventionally from
baseline or a-wave trough to positive peak; a-wave amplitude was
measured from baseline to negative peak at the maximal stimulus.
For isolating cone pathway function, dogs were light-adapted and 29
Hz flicker ERGs evoked with white flash stimuli (0.4 log
cd.s.m.sup.-2) on a background (0.8 log cd.m.sup.-2); amplitudes
were measured between successive negative and positive peaks and
timing from stimulus to the next positive peak. Ocular axial length
and pupil diameter were measured for each experiment to permit
calculation of retinal illuminance.
[0086] The restoration of retinal/visual function in RPE65 mutant
dogs by subretinal AAV-RPE65 was demonstrated by the results of the
above-described ERGs. A comparison of dark-adapted ERGs evoked by
increasing intensities of blue light stimuli in a control dog with
ERGs to the same stimuli in RPE65 mutant dog BR33 showed the
affected animal had elevated thresholds, reduced amplitudes and
waveform shape changes (i.e., b-waves but no detectable a-waves).
Over a 5 log unit range of increasing stimulus intensity, the ERG
of normal dogs responded with increasing amplitude of bipolar cell
(b-wave) and photoreceptor (a-wave) components. At all intensities
these signals were dominated by rod photoreceptor retinal pathways.
Compared to normal dogs, the threshold stimulus required to elicit
an ERG response from 4 month old RPE65 mutant dogs was elevated by
over 4.5 log units.
[0087] Retinal function was dramatically improved in eyes treated
with subretinal AAV-RPE65, compared to pre-treatment recordings.
After subretinal AAV-RPE65 therapy, the mutant dog showed a vastly
improved b-wave threshold, a large increase of a- and b-wave
amplitudes (although not to normal levels) and an ERG waveform
shape that is similar to controls. Responses from the right eye of
BR33 had b-wave thresholds lower by .about.4 log units than
pre-treatment, and appeared similar to normal.
[0088] The details of photoreceptor function were analyzed by the
amplitude and timing of the ERG photoresponses evoked by 2.8 log
scot-cd.s.m.sup.-2 flashes. Recordings from three control dogs
showed .about.250 .mu.LV saturated amplitudes peaking between 4.5
to 6 ms. Photoreceptor function was near noise level in three
untreated eyes of RPE65 mutant dogs and two eyes treated with
intravitreal AAV-RPE65. Photoresponses (of reduced amplitude but
normal timing) were present in all three eyes that received
subretinal AAV-RPE65. ERG photoresponses in the three subretinally
injected eyes showed maximal amplitudes of 27, 36 and 58 .mu.V,
representing .about.16% of normal (mean.+-.SD=246.+-.95 .mu.V;
n=7).
[0089] Small responses evoked at higher intensities lacked an
a-wave. Higher energy stimuli and recording criteria that elicit,
in normal dogs, saturated ERG photoresponses originating from
photoreceptors yielded no detectable signals in affected animals. A
flicker ERG response, representing isolated cone pathway function
in normals, was absent in affected animals. Photoresponse
amplitudes in subretinally injected eyes were significantly
different (P<0.05) than the amplitudes in untreated eyes
(14.+-.3.4 .mu.V; n=3).
[0090] Flicker ERGs in the same eyes as described in the
immediately preceding paragraphs demonstrated a lack of detectable
cone-mediated responses from RPE65 mutant dogs with untreated or
intravitreally treated eyes. All eyes with subretinal AAV-RPE65
treatment recovered cone flicker responses. Cone flicker ERGs were
readily recordable post-treatment; amplitudes ranged from 4 to 6
.mu.V, representing .about.16% of normal (30.+-.8 .mu.V).
Intravitreally injected eyes showed no difference from untreated
eyes for all measured ERG parameters.
2. Pupillometry
[0091] Transmission of retinal activity to higher visual pathways
was demonstrated by pupillometry. Dogs were dark-adapted for more
than 3 hours and pupil responses were obtained sequentially from
each eye using full-field green stimuli (-3.2 to +3.0 log
scot-cd.m.sup.-2) of .about.2 second duration. Pupils were imaged
with a video camera under infrared illumination and continuously
recorded on a VCR. Dynamic changes in pupil diameters were measured
from single frames displayed on the video monitor in relation to
the timing of each stimulus. Pupil responses were calculated by
subtracting the smallest pupil diameter achieved within 2 seconds
after the stimulus onset from the diameter measured in the
dark.
[0092] All tested pupils constricted in response to high intensity
stimuli. Pupil response as a function of stimulus intensity showed
3.8 log unit elevation of threshold (1 mm response criterion) in
untreated eyes (n=3; two eyes of BR46 and one eye of BR29) compared
to normal eyes (n=3). Eyes treated with subretinal AAV (n=2; BR33
and BR47) had 0.8 log unit lower thresholds compared to untreated
eyes.
[0093] A change in pupil diameter was noted in response to 2.5 log
cd.m.sup.-2 green stimulus in one eye of three representative dogs;
untreated (BR46), subretinal AAV treated (BR33) and a normal
control.
[0094] At a suprathreshold intensity, pupillary constriction was
greatest in normal dogs and least in untreated RPE65 mutant dogs.
Subretinally-treated eye of BR33 responded midway between normal
and untreated. The threshold intensity to reach a criterion
pupillary response was improved in subretinally-treated eyes
compared with untreated eyes.
[0095] Consistent with ERG and pupillometry results, at 104 days
post-treatment, flash evoked visual cortical potentials to a series
of increasing intensities of blue light (Wratten 47) in the
dark-adapted state and recorded definite waveforms from the
subretinally-treated eye. In contrast there were no consistent
waveforms at any intensity from the eye treated intravitreally.
3. Behavioral Testing
[0096] Qualitative visual assessment of the 3 treated animals was
performed at 4 months post injection using an obstacle course and
observers masked to the experimental design. Visual behavior was
also documented by video recording. Results of behavioral testing
were consistent with the electrophysiological results.
[0097] For example, dog BR33 was consistently (5/5 observers)
scored as "normally sighted" under photopic (room lighting)
conditions. Under dim red light this dog consistently avoided
objects either directly in front of her, or to her right (the side
injected subretinally), but consistently failed to avoid objects on
the left (injected intravitreally). In contrast, the untreated
control affected dog, BR46 walked into objects ahead of her and at
either side.
[0098] Table 1 provides the data collected from the procedures
performed on the eyes of four RPE65 mutant dogs. In the Table, age
is recorded as days postnatal. The abbreviation Rt is used for
right eye, while left is indicated for left eye. The routes of
injection are identified as SR for subretinal injection, IV for
intravitreal injection, and NI for not injected. The doses are
reported as No..times.10.sup.10 infectious particles of recombinant
AAV-RPE65 virus injected. Baseline ERGs were recorded 2 weeks prior
to injection. Rescue Effect was assessed by ERGs recorded 95 days
after injection. Positive effect is indicated by POS. NEG indicates
no effect apparent.
TABLE-US-00001 TABLE 1 ERG Age at Route of Volume Age at Rescue
Animal Day 0 Eye Injec'n Dose (.mu.L) ERG Effect BR29 132 Rt SR 3.7
150 227 POS Left NI -- -- 227 NEG BR33 124 Rt SR 4.6 200 219 POS
Left IV 4.6 200 219 NEG BR47 108 Rt SR 4.6 200 203 POS Left IV 4.6
200 203 NEG BR46 108 Rt NI -- -- 203 NEG Left NI -- -- 203 NEG
[0099] All references and documents disclosed above are
incorporated by reference herein. Numerous modifications and
variations of the present invention are included in the
above-identified specification and are expected to be obvious to
one of skill in the art. Such modifications and alterations to the
compositions and processes of the present invention are believed to
be encompassed in the scope of the claims appended hereto.
* * * * *